Day 2 Agenda | Allogeneic Cell Therapies Summit 2022

9-12 May, 2022

Boston, MA

Register & Pay Before Friday
28th January & Save up to $1,900

Day One

Tuesday, May 10, 2022

Day Two

Wednesday, May 11, 2022

8:00 am Coffee Room Networking

8:45 am Chair’s Opening Remarks

Sven Kili CEO, Antion Biosciences

9:00 am Industry Leaders Fireside Chat

Blake Aftab CSO, Adicet Bio
Pascal Touchon CEO, Atara Biotherapeutics
Carrie Brownstein CMO, Cellectis

Synopsis

For more information on this session, please download the full event guide.

10:00 am Tech Slam

Synopsis

Quickfire 10-minute presentations from the leading solution providers in the space.

11:00 am Morning Refreshment Break

Track 1: Pre-Clinical

Chair: Sven Kili, CEO, Antion Biosciences

Promises & Challenges of Allogeneic Therapies for Solid Tumors

11.30 TCR-NK Cells: A Novel Platform Combining Specific TCR Targeting with Broad NK Cell Cancer Activity

Luise Weigand, Head of Research, Zelluna Immunotherapy

For more information on this session, please download the full event guide.

12.00 Key Considerations for the Development of Best-in-Class Allogeneic CAR-T Cell Therapies for Solid Tumors

Beatriz Aranda-Orgilles, Senior Scientist & Team Leader Immuno-Oncology, Cellectis

For more information on this session, please download the full event guide.

12.30 Lunch Refreshment Break

Exploring Approaches to Best Target Cancer Cells

2.30 Precision Targeting of AML with Logic Gated CAR-NK Cells

Gary Lee, CSO, Senti Biosciences

For more information on this session, please download the full event guide.

3.30 Allogeneic G-NK Cells Combined with Monoclonal Antibodies for Enhanced Tumor Targeting

Austin Bigley, VP, Director of Research & Development, Indapta Therapeutics

For more information on this session, please download the full event guide.

Track 2: Translational

Chair: Erika von Euw, VP, Translational Research, Deverra Therapeutics

Exploring the Need for Pre-Conditioning Strategies to Improve Engraftment

11.30 Universal Gene Modification Strategies to Obviate the Need for Immunosuppressive Agents

Evren Alici, Head of Cell & Gene Therapy, Karolinska Institutet

For more information on this session, please download the full event guide.

12.00 Roundtable Session: To Lymphodeplete or Not to Lymphodeplete?

For more information on this session, please download the full event guide.

12.30 Lunch Refreshment Break

Clinical Translation Data: Setting Up For Success in First Human Trials

2.30 Exploiting Non-Gene Edited Technology for the Treatment of mCRC and MM

David Gilham, CSO, Celyad Oncology

For more information on this session, please download the full event guide.

3.30 New Class of Cancer Vaccine Based on a Off-the-Shelf Antigen Presenting Cell Line

Eric Halioua, CEO, PDC*Line Pharma

For more information on this session, please download the full event guide.

Track 3: Manufacturing

Chair: TBC

Achieving Reproducibility & Comparability in Allogeneic Manufacture

11.30 Ensuring Product Quality and Consistency in Manufacture of Off-the-Shelf Products

Martin Giedlin, VP, Head of Technical Operations, Senti Biosciences

For more information on this session, please download the full event guide.

12.00 The Evolution of an Allogeneic Process Whilst in the Clinic

Brian Culley, CEO, Lineage Cell Therapeutics

For more information on this session, please download the full event guide.

12.30 Lunch Refreshment Break

Setting Up for Late Stage or Commercial Manufacture

2.30 Considerations for the Design of a Cost-Effective Commercial Facility

James Glover, SVP, Commercial Manufacture, Athersys

For more information on this session, please download the full event guide.

3.30 Preparing for Commercialization of an Off-the-Shelf Product

Daniel Bright, Global Program Director of Global Technical Operations, Ferring Pharmaceuticals

For more information on this session, please download the full event guide.

Track 4: Supply/Storage

Chair: TBC

Technology Ecosystem for Supply

11.30 Combining CMC and Clinical Development to Build an Effective Allogeneic Supply Chain

Tim Jansen, Director, Supply Chain Strategic Sourcing, Sana Biotechnology

For more information on this session, please download the full event guide.

12.00 Transitioning Supply Chains to Fit an Off-the-Shelf Model in Preparation for Clinical Operations

Rakibou Ouro-Djobo, Associate Director, Clinical Supply Chain, TCR2 Therapeutics

For more information on this session, please download the full event guide.

12.30 Lunch Refreshment Break

Turbocharging Digitalization of Delivery

2.30 Establishing an Allogeneic Supply Chain with Digital Capabilities

Stephen Chen, CTO & COO, NKGen Biotech

For more information on this session, please download the full event guide.

3.30 Roundtable Session: Designing a “Dream Digital Ecosystem” to Map Product & Patient Journey

For more information on this session, please download the full event guide.

4:00 pm Afternoon Refreshment Break & Networking

4:30 pm Establishing An Efficient Development Roadmap in Allogeneic Cell Therapy to Accelerate Speed to the Clinic and Market

Zhimei Du VP, Process Sciences, Atara Biotherapeutics

Synopsis

For more information on this session, please download the full event guide.

Clinical Perspectives to Off-the-Shelf Therapies

5:00 pm The Patient Experience: Solid Tumor Cell Therapies in the Context of Standard of Care

Brian Van Tine Professor, Medicine & Pediatrics, Washington University School of Medicine in St. Louis

Synopsis

For more information on this session, please download the full event guide.

5:30 pm Closing Remarks & Close of Conference

Pre-Conference Workshop Day

Conference Day One